8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2025

DERMATA

THERAPEUTICS, INC.

(Exactname of registrant as specified in its charter)

Registrant’s telephone number, including area code: (858) 800-2543

N/A

(Formername or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities

registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item8.01 Other Events.

On September 17, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s presentation of an abstract at the European Academy of Dermatology and Venereology Congress 2025. The abstract contains clinical data from the Company’s XYNGARI™ (also known as DMT310) Phase 3 Spongilla Treatment of Acne (STAR-1) clinical trial.

In an intent to treat analysis, the Company saw statistically significant differences in IGA treatment success, mean change in inflammatory lesion count, and non-inflammatory lesion count and percent change in inflammatory lesion count, and non-inflammatory lesion count at week 4, 8, and 12 when compared to placebo.

Investigator Global Assessment (IGA): Patients achieving a 2-point reduction AND score of 0 or 1 (“clear” or “almost clear”)

Investigator Global Assessment (IGA): Patients achieving a 2-point reduction

Mean change from baseline in inflammatory lesion count

Percent change from baseline in inflammatory lesion count

Mean change from baseline in non-inflammatory lesion count

Percent change from baseline in non-inflammatory lesion count

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.